Evidence map›Paper›PMID 38323009›Full record

ArticleiScience2024

RNA helicase DDX3 regulates RAD51 localization and DNA damage repair in Ewing sarcoma.

Matthew E Randolph, Marwa Afifi, Aparna Gorthi, Rachel Weil, Breelyn A Wilky, Joshua Weinreb, Paul Ciero, Natalie Ter Hoeve, Paul J van Diest, Venu Raman and 2 more

Open access · goldAbstract read
In one paragraph

Article in iScience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Matthew E RandolphDepartment of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Marwa AfifiLaboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Aparna GorthiGreehey Children's Cancer Research Institute and Department of Cell Systems & Anatomy, UT Health San Antonio, San Antonio, TX, USA.
Rachel WeilDepartment of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Breelyn A WilkyDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Joshua WeinrebDepartment of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Paul CieroDepartment of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Natalie Ter HoeveDepartment of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Paul J van DiestDepartment of Pathology, University Medical Centre Utrecht, Utrecht, the Netherlands.
Venu RamanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Alexander J R BishopGreehey Children's Cancer Research Institute and Department of Cell Systems & Anatomy, UT Health San Antonio, San Antonio, TX, USA.
David M LoebDepartment of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY, USA.
Albert Einstein College of Medicine · USCancer Research Institute of the Slovak Academy of Sciences · SKJohns Hopkins University · USUniversity Medical Center Utrecht · NLNational Cancer Institute · US

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
Support for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5M
Dysregulated transcription processes in Ewing sarcoma:R01CA241554 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BISHOP, ALEXANDER JAMES · 2020 to 2025
$2.3M
Improving etoposide treatment of Ewing's sarcomaR01CA152063 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BISHOP, ALEXANDER JAMES · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA013330NCI NIH HHS R01 CA152063NCI NIH HHS R01 CA241554NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766
6 · The paper itself

Abstract

We previously demonstrated that RNA helicase DDX3X (DDX3) can be a therapeutic target in Ewing sarcoma (EWS), but its role in EWS biology remains unclear. The present work demonstrates that DDX3 plays a unique role in DNA damage repair (DDR). We show that DDX3 interacts with several proteins involved in homologous recombination, including RAD51, RECQL1, RPA32, and XRCC2. In particular, DDX3 colocalizes with RAD51 and RNA:DNA hybrid structures in the cytoplasm of EWS cells. Inhibition of DDX3 RNA helicase activity increases cytoplasmic RNA:DNA hybrids, sequestering RAD51 in the cytoplasm, which impairs nuclear translocation of RAD51 to sites of double-stranded DNA breaks, thus increasing sensitivity of EWS to radiation treatment, both

Indexed as

BiochemistryBiological sciencesCancerCell biologyMolecular biologyNatural sciences

Identifiers

PMID38323009
PMCPMC10844834
OpenAlexW4391065229

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.